P
Peter L. Collins
Researcher at National Institutes of Health
Publications - 14
Citations - 2853
Peter L. Collins is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Transcription (biology) & RNA. The author has an hindex of 13, co-authored 14 publications receiving 2746 citations.
Papers
More filters
Journal ArticleDOI
Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development
TL;DR: It should be possible to introduce defined changes into infectious RSV using the M2(ORF1) protein, consistent with its recent identification as a transcription elongation factor and confirms its importance for RSV gene expression.
Journal ArticleDOI
Viral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis
TL;DR: Human respiratory syncytial virus (RSV) was first isolated in 1956 from a laboratory chimpanzee with upper respiratory tract disease and was quickly determined to be of human origin and was shown to be the leading virus.
Journal ArticleDOI
Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.
Peter L. Collins,José A. Melero +1 more
TL;DR: RSV is notable for a historic, tragic pediatric vaccine failure involving a formalin-inactivated virus preparation that was evaluated in the 1960s and that was poorly protective and paradoxically primed for enhanced RSV disease.
Journal ArticleDOI
Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus.
TL;DR: It is proposed that this activity renders nucleocapsids synthetically quiescent prior to incorporation into virions as well as in the case of a dicistronic minigenome, sequential transcription.
Journal ArticleDOI
Identification of a Recombinant Live Attenuated Respiratory Syncytial Virus Vaccine Candidate That Is Highly Attenuated in Infants
Ruth A. Karron,Peter F. Wright,Robert B. Belshe,Bhagvanji Thumar,Roberta Casey,Frances K. Newman,Fernando P. Polack,Valerie B. Randolph,Anne M. Deatly,Jill G. Hackell,William C. Gruber,Brian R. Murphy,Peter L. Collins +12 more
TL;DR: In this article, two live attenuated, recombinantly derived RSV vaccine candidates, rA2cp248/404/1030 Delta SH and rA 2cp248,404,1030 delta SH, were evaluated in 31 adults and 95 children >/=6 months old.